Merck (MRK) Stock News

Merck announced first-time pivotal Phase 3 results from three oncology trials will be presented at ESMO 2026 Presidential Symposia. INTerpath-001 showed intismeran autogene plus KEYTRUDA improved recurrence-free and distant metastasis-free survival versus KEYTRUDA alone in resected stage IIB-IV melanoma. TroFuse-005 is the first Phase 3 trial of a TROP2-directed ADC to show overall survival and progression-free survival benefit in advanced endometrial cancer. KEYNOTE-C93 supports first-line KEYTRUDA monotherapy in dMMR endometrial cancer. Merck will host an investor event Oct. 26.

Merck (MRK) announced an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor. SciBrunch receives $400M upfront and is eligible for up to $2.13B in milestone payments. Merck will record a $400M pretax charge (~$0.13/share) in Q3 2026. The transaction has closed.

Merck & Co. advances two Phase 3 trials of ifinatamab deruxtecan in CRPC, ESCC.

Merck's remigromig, a first-in-class tri-specific Wnt pathway agonist, showed non-inferiority to ranibizumab in the Phase 2b/3 BRUNELLO study for diabetic macular edema. Safety signals include higher rates of proliferative diabetic retinopathy and vitreous hemorrhage. Results to be presented at AAO on Oct. 10.

Merck reported that remigromig met its primary endpoint, showing non-inferiority to ranibizumab for visual acuity improvement at 52 weeks. The data supports regulatory filing plans.

Guggenheim lifts Merck target price to $170 from $146.

Merck and Moderna announced positive Phase 3 results for intismeran autogene, an mRNA personalized cancer vaccine, combined with Keytruda in melanoma. The trial met recurrence-free and distant metastasis-free survival endpoints. Full data to be presented at a medical meeting; regulatory submissions to begin.

Upgrades and downgrades: AVAL, ENTG, IEX, ISRG, JOYY, MRK, OKTA up; APGE, ATAI, CRDF, GAP, LEGN, NVO, ONON, TME down.